for people ages up to 12 months (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Srinath Sanda



This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children < 1 year of age with congenital hyperinsulinism.

Official Title

A Phase 2 Proof-of-Concept Study of CSI-Glucagon™ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism


This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind parallel group study with open-label follow-up designed to evaluate the efficacy of CSI-Glucagon™ for the prevention of hypoglycemia with lower IV glucose infusion rates when delivered subcutaneously to patients up to 1 year of age with congenital hyperinsulinism. CSI-Glucagon™ is expected to provide a better inpatient treatment option compared to the current standard of care.

The study will consist of three phases:

  1. Baseline Phase: First is a baseline stabilization phase during which concomitant therapy with octreotide and diazoxide will be safely weaned and continuous enteric feed will be held constant to the degree possible, with the only factors varying being meal size and IV glucose infusion rate (GIR) adjusted by a set plasma glucose measurement driven algorithm.
  2. Blinded, Randomized Treatment Phase: Following the stabilization phase, subjects will be randomly assigned to blinded treatment with either glucagon or placebo, which will be delivered for up to 48 hours with an OmniPod® infusion pump with the controller set to a starting basal rate for glucagon of 5 μg/kg/hr and GIR adjustments used to maintain euglycemia. After 48 hours of blinded treatment, all subjects will transition to open-label active treatment. However, if GIR reduction from baseline is < 20% at 24 hours, subjects will be transitioned early to the open-label phase.
  3. Open-label Treatment Phase: The third study period will involve use of CSI-Glucagon™ to manage blood glucose with minimal GIR for up to 28 days of cumulative exposure.


Congenital Hyperinsulinism hypoglycemia Hyperinsulinism Glucagon Glucagon-Like Peptide 1 CSI-Glucagon


You can join if…

Open to people ages up to 12 months

  1. Diagnosed with hyperinsulinism:
  2. Biochemical; detectable insulin (i.e., ≥1 µIU/L) at time of hypoglycemia (i.e,blood glucose <50 mg/dl), and/or suppressed free fatty acids (FFA), and/or suppressed beta-hydroxybutyrate (BOHB) and/or glycemic response to glucagon at time of hypoglycemia.
  3. Absolute necessity of intravenous glucose to prevent hypoglycemia:
  4. Having failed diazoxide therapy as defined by inadequacy of 5 days maximum dose of diazoxide to eliminate the need for IV glucose, not necessarily that diazoxide has no effect.
  5. May be on diazoxide and/or octreotide, but these drugs will be weaned off prior to randomization.
  6. May be on dextrose feeds.
  7. Patient may be a participant in other study protocols such as observational studies,as long as no investigational intervention has taken place within 24 hrs. prior to screening.
  8. Less than 12 months of age at screening.

You CAN'T join if...

  1. History of allergy to glucagon or excipients in the CSI-Glucagon formulation.
  2. Currently receiving, or less than 12 hours removed from IV glucagon treatment that resulted in a best achievable GIR > 8 mg/(kg*min), prior to the start of study drug.
  3. Diazoxide naïve or within five days of starting diazoxide.
  4. Receiving steroids at doses larger than 20 mg/m2/day (hydrocortisone equivalent).
  5. Patients with sepsis.
  6. Receiving alpha or beta agonists for blood pressure support.
  7. Received an investigational or other study drug within 5 half-lives of drug.
  8. Body weight less than or equal to 2.3 kg/5.0 lbs.
  9. History of pancreatectomy and GIR < 8 mg/(kg*min) after weaning of all concomitant therapies.


  • UCSF School of Medicine, Division of Pediatric Endocrinology accepting new patients
    San Francisco California 94143 United States
  • UCLA Mattel Children's Hospital not yet accepting patients
    Los Angeles California 90095 United States


accepting new patients
Start Date
Completion Date
Xeris Pharmaceuticals
Phase 2
Lead Scientist
Srinath Sanda
Study Type
Last Updated